A COMPREHENSIVE REVIEW ON THE MULTIFACETED INTERACTIONS BETWEEN HOST IMMUNITY AND VIRAL PATHOGENESIS IN COVID-19

Authors

  • MAIREMBAM STELIN SINGH Department of Biochemistry, SCLS, Jamia Hamdard, New Delhi, India. Department of Zoology, Rajiv Gandhi University, Arunachal Pradesh, India https://orcid.org/0009-0008-0117-5263
  • SAILU YELLABOINA All India Institute of Medical Sciences, Bibinagar, Hyderabad, Telangana-508126, India https://orcid.org/0000-0002-5851-3824
  • MAIRAJ AHMED ANSARI Department of Biotechnology, SCLS, Jamia Hamdard, New Delhi, India. Centre for Virology, SIST, Jamia Hamdard, New Delhi, India

DOI:

https://doi.org/10.22159/ijap.2024v16i4.50576

Keywords:

COVID-19, HPI, ACE2, Multiomics, Host immunity, Viral proteins

Abstract

The Corona Virus Disease (COVID-19) pandemic has presented unparalleled challenges, marked by a wide array of clinical presentations spanning from asymptomatic carriage to severe respiratory compromise and multi-organ dysfunction. It is crucial to comprehend the intricate interplay between host immunity and viral pathogenesis to elucidate disease mechanisms and guide therapeutic strategies. This review delves into the multifaceted interactions between host immunity and viral pathogenesis in COVID-19, with a particular focus on the impact of host factors such as age, sex, comorbidities, and genetic predisposition on disease severity. Utilizing state-of-the-art methodologies, including multiomics approaches, has yielded an expansive molecular portrayal of COVID-19, furnishing innovative perspectives on host immune reactions, viral pathogenicity, and disease advancement. Establishing standardized methodologies for data analysis and interpretation while concurrently addressing ethical considerations and promoting interdisciplinary collaboration are crucial steps in advancing our comprehension of COVID-19 pathogenesis. Despite obstacles like complexities in data integration, this review highlights the imperative of persistent endeavors in deciphering the complex interactions between hosts and pathogens to alleviate the global health ramifications of COVID-19.

Downloads

Download data is not yet available.

References

Mallah SI, Ghorab OK, Al-Salmi S, Abdellatif OS, Tharmaratnam T, Iskandar MA. COVID-19: breaking down a global health crisis. Ann Clin Microbiol Antimicrob. 2021;20(1):35. doi: 10.1186/s12941-021-00438-7, PMID 34006330, PMCID PMC8129964.

Peng M. Outbreak of COVID-19: an emerging global pandemic threat. Biomed Pharmacother. 2020;129:(110499). doi: 10.1016/j.biopha.2020.110499, PMID 32768974, PMCID PMC7334916.

Hassan SA, Sheikh FN, Jamal S, Ezeh JK, Akhtar A. Coronavirus (COVID-19): a review of clinical features, diagnosis, and treatment. Cureus. 2020;12(3):e7355. doi: 10.7759/cureus.7355, PMID 32328367, PMCID PMC7170025.

Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, evaluation, and treatment of coronavirus (COVID-19). StatPearls Publishing; 2023.

Lake MA. What we know so far: COVID-19 current clinical knowledge and research. Clin Med (Lond). 2020;20(2):124-7. doi: 10.7861/clinmed.2019-coron, PMID 32139372, PMCID PMC7081812.

Fung TS, liu DX. Human coronavirus: host-pathogen interaction. Annu Rev Microbiol. 2019;73(1):529-57. doi: 10.1146/annurev-micro-020518-115759, PMID 31226023.

Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses. 2020;12(4):372. doi: 10.3390/v12040372.

Li C, He Q, Qian H, liu J. Overview of the pathogenesis of COVID 19 (Review). Exp Ther Med. 2021;22(3):1011. doi: 10.3892/etm.2021.10444, PMID 34345293.

Wu F, Zhao S, Yu B, Chen YM, Wang W, Hu Y. Complete genome characterisation of a novel coronavirus associated with severe human respiratory disease in Wuhan, China. bioRxiv; 2020. doi: 10.1101/2020.01.24.919183.

Mehta S, Sharma N, Jain S. Impact of COVID-19 pandemic on maternal mortality ratio in a tertiary care hospital of Rajasthan: a retrospective analysis. Asian J Pharm Clin Res. 2022;15(10):39-41. doi: 10.22159/ajpcr.2022.v15i10.45535.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5, PMID 31986264, PMCID PMC7159299.

Li C, He Q, Qian H, liu J. Overview of the pathogenesis of COVID-19 (Review). Exp Ther Med. 2021;22(3):1011. doi: 10.3892/etm.2021.10444, PMID 34345293, PMCID PMC8311250.

Skariyachan S, Challapilli SB, Packirisamy S, Kumargowda ST, Sridhar VS. Recent aspects on the pathogenesis mechanism, animal models and novel therapeutic interventions for middle East Respiratory Syndrome coronavirus infections. Front Microbiol. 2019;10:569. doi: 10.3389/fmicb.2019.00569, PMID 30984127, PMCID PMC6448012.

Park SH. An impaired inflammatory and innate immune response in COVID-19. Mol Cells. 2021;44(6):384-91. doi: 10.14348/molcells.2021.0068, PMID 34098591, PMCID PMC8245320.

Hosseini A, Hashemi V, Shomali N, Asghari F, Gharibi T, Akbari M. Innate and adaptive immune responses against coronavirus. Biomed Pharmacother. 2020;132:(110859). doi: 10.1016/j.biopha.2020.110859, PMID 33120236, PMCID PMC7580677.

Taefehshokr N, Taefehshokr S, Hemmat N, Heit B. COVID-19: perspectives on innate immune evasion. Front Immunol. 2020;11:580641. doi: 10.3389/fimmu.2020.580641, PMID 33101306, PMCID PMC7554241.

Ahmadpoor P, Rostaing L. Why the immune system fails to mount an adaptive immune response to a COVID-19 infection. Transpl Int. 2020;33(7):824-5. doi: 10.1111/tri.13611, PMID 32236983.

Lopez L, Sang PC, Tian Y, Sang Y. Dysregulated interferon response underlying severe COVID-19. Viruses. 2020;12(12):1433. doi: 10.3390/v12121433, PMID 33322160, PMCID PMC7764122.

Uday Srikar VS, Naga Swarna YV, Yugandhar G. The loss of smell (anosmia) in COVID 19 patients-to what extent it helps in the diagnosis of COVID 19 and factors influencing its recovery-a clinical study. Asian J Pharm Clin Res. 2022;15(2):135-7. doi: 10.22159/ajpcr.2022.v15i2.43872.

Farzi R, Aghbash PS, Eslami N, Azadi A, Shamekh A, Hemmat N. The role of antigen-presenting cells in the pathogenesis of COVID-19. Pathol Res Pract. 2022;233:(153848). doi: 10.1016/j.prp.2022.153848, PMID 35338971, PMCID PMC8941975.

Oliveira DS, Medeiros NI, Gomes JA. Immune response in COVID-19: what do we currently know? Microb Pathog. 2020;148:104484. doi: 10.1016/j.micpath.2020.104484, PMID 32916246, PMCID PMC7480770.

Nikhra V. The agent and host factors in COVID-19: exploring pathogenesis and therapeutic implications. Biomed J Sci Techn Res. 2020;27:20669-81.

Nepomuceno MR, Acosta E, Alburez Gutierrez D, Aburto JM, Gagnon A, Turra CM. Besides population age structure, health and other demographic factors can contribute to understanding the COVID-19 burden. Proc Natl Acad Sci USA. 2020;117(25):13881-3. doi: 10.1073/pnas.2008760117, PMID 32576710, PMCID PMC7322063.

Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: a comparison with young and middle-aged patients. J Infect. 2020;80(6):e14-8. doi: 10.1016/j.jinf.2020.03.005, PMID 32171866.

Mukherjee S, Pahan K. Is COVID-19 gender-sensitive? J Neuroimmune Pharmacol. 2021;16(1):38-47. doi: 10.1007/s11481-020-09974-z, PMID 33405098, PMCID PMC7786186.

Yang J, Tian C, Chen Y, Zhu C, Chi H, Li J. Obesity aggravates COVID-19: an updated systematic review and meta-analysis. J Med Virol. 2021;93(5):2662-74. doi: 10.1002/jmv.26677, PMID 33200825, PMCID PMC7753795.

Gülsen A, König IR, Jappe U, Dromann D. Effect of comorbid pulmonary disease on the severity of COVID-19: a systematic review and meta-analysis. Respirology. 2021;26(6):552-65. doi: 10.1111/resp.14049, PMID 33955623, PMCID PMC8207055.

Singh J, Malik P, Patel N, Pothuru S, Israni A, Chakinala RC. Kidney disease and COVID-19 disease severity-systematic review and meta-analysis. Clin Exp Med. 2022;22(1):125-35. doi: 10.1007/s10238-021-00715-x, PMID 33891214, PMCID PMC8063780.

Tassone D, Thompson A, Connell W, lee T, Ungaro R, An P, Ding Y, Ding NS. Immunosuppression as a risk factor for COVID-19: a meta-analysis. Intern Med J. 2021;51(2):199–205. doi: 10.1111/imj.15142, PMCID: PMC8014211.

Gibson PG, Qin L, Puah SH. COVID-19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre-COVID-19 ARDS. Med J Aust. 2020;213(2):54-56.e1. doi: 10.5694/mja2.50674, PMID 32572965, PMCID PMC7361309.

Qiu Y, Chen X, Shi W. Impacts of social and economic factors on the transmission of coronavirus disease 2019 (COVID-19) in China. J Popul Econ. 2020;33(4):1127-72. doi: 10.1007/s00148-020-00778-2, PMID 32395017, PMCID PMC7210464.

Hawkins RB, Charles EJ, Mehaffey JH. Socio-economic status and COVID-19-related cases and fatalities. Public Health. 2020;189:129-34. doi: 10.1016/j.puhe.2020.09.016, PMID 33227595, PMCID PMC7568122.

Hu J, Li C, Wang S, Li T, Zhang H. Genetic variants are identified to increase risk of COVID-19 related mortality from UK Biobank data. Hum Genomics. 2021;15(1):10. doi: 10.1186/s40246-021-00306-7, PMID 33536081, PMCID PMC7856608.

Pairo Castineira E, Rawlik K, Bretherick AD, Qi T, Wu Y, Nassiri I. GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19. Nature. 2023;617(7962):764–8. doi: 10.1038/s41586-023-06034-3, PMCID: PMC10208981.

Horowitz JE, Kosmicki JA, Damask A, Sharma D, Roberts GH, Justice AE. Genome-wide analysis provides genetic evidence that ACE2 influences COVID-19 risk and yields risk scores associated with severe disease. Nat Genet. 2022;54(4):382–92. doi: 10.1038/s41588-021-01006-7, PMCID: PMC9005345.

Langton DJ, Bourke SC, Lie BA, Reiff G, Natu S, Darlay R. The influence of HLA genotype on the severity of COVID-19 infection. HLA. 2021;98(1):14-22. doi: 10.1111/tan.14284, PMID 33896121, PMCID PMC8251294.

Araujo A, Sgorlon G, Aguiar LE, Cidrao MH, Teixeira KS, Villalobos Salcedo JM. Influence of polymorphic variations of IFNL, HLA, and IL-6 genes in severe cases of COVID-19. Exp Biol Med (Maywood). 2023;248(9):787-97. doi: 10.1177/15353702231181343, PMID 37452704, PMCID PMC10350587.

Davitt E, Davitt C, Mazer MB, Areti SS, Hotchkiss RS, Remy KE. COVID-19 disease and immune dysregulation. Best Pract Res Clin Haematol. 2022;35(3):101401. doi: 10.1016/j.beha.2022.101401, PMID 36494149, PMCID PMC9568269.

Jamal M, Bangash HI, Habiba M, lei Y, Xie T, Sun J, Wei Z, Hong Z, Shao l, Zhang Q. Immune dysregulation and system pathology in COVID-19. Virulence. 2021;12(1):918-36. doi: 10.1080/21505594.2021.1898790, PMCID: PMC7993139.

Lagunas Rangel FA, Chavez Valencia V. High IL-6/IFN-γ ratio could be associated with severe disease in COVID-19 patients. J Med Virol. 2020;92(10):1789-90. doi: 10.1002/jmv.25900, PMID 32297995, PMCID PMC7262117.

Ganji A, Farahani I, Khansarinejad B, Ghazavi A, Mosayebi G. Increased expression of CD8 marker on T-cells in COVID-19 patients. Blood Cells Mol Dis. 2020;83:(102437). doi: 10.1016/j.bcmd.2020.102437, PMID 32325421, PMCID PMC7194879.

Mohammed N, Kamal Saeed AS. COVID-19 disease and autoimmune disorders: A mutual pathway. World J Methodol. 2022 Jul 20;12(4):200-23. doi: 10.5662/wjm.v12.i4.200, PMID 36159097, PMCID: PMC9350728.

Lim YX, Ng YL, Tam JP, liu DX. Human coronaviruses: a review of virus-host interactions. Diseases. 2016;4(3):26. doi: 10.3390/diseases4030026, PMID 28933406, PMCID PMC5456285.

Tsukagoshi H, Shinoda D, Saito M, Okayama K, Sada M, Kimura H. Relationships between viral load and the clinical course of COVID-19. Viruses. 2021;13(2):304. doi: 10.3390/v13020304, PMID 33672005, PMCID PMC7919281.

Dadras O, Afsahi AM, Pashaei Z, Mojdeganlou H, Karimi A, Habibi P. The relationship between COVID-19 viral load and disease severity: a systematic review. Immun Inflamm Dis. 2022;10(3):e580. doi: 10.1002/iid3.580, PMID 34904379, PMCID PMC8926507.

Biju P, Pallavi RV, Dsouza S, Asif Iqbal M, Ahmed G. A review on the impact of the COVID-19 pandemic on the health care sector. Int J Pharm Pharm Sci. 2021;13(10):1-6. doi: 10.22159/ijpps.2021v13i10.42566.

Rabaan AA, Tirupathi R, Sule AA, Aldali J, Mutair AA, Alhumaid S. Viral dynamics and real-time RT-PCR Ct values correlation with disease severity in COVID-19. Diagnostics (Basel). 2021;11(6):1091. doi: 10.3390/diagnostics11061091, PMID 34203738, PMCID PMC8232180.

Hadj Hassine I. COVID-19 vaccines and variants of concern: a review. Rev Med Virol. 2022;32(4). doi: 10.1002/rmv.2313.

Zahmatkesh S. Review of concerned SARS-CoV-2 variants like Alpha (B. 1.1. 7). Beta (B. 1.351), Gamma (P. 1). Delta (B. 1.617. 2), and Omicron (B. 1.1. 529), as well as novel methods for reducing and inactivating SARS-CoV-2 mutants in wastewater treatment facilities. Journal of Hazardous Materials Advances. 2022;7:100140. doi: 10.1016/j.hazadv.2022.100140, PMID: 37520798.

Hajizadeh F, Khanizadeh S, Khodadadi H, Mokhayeri Y, Ajorloo M, Malekshahi A. SARS-COV-2 RBD (Receptor binding domain) mutations and variants (A sectional-analytical study). Microb Pathog. 2022;168:(105595). doi: 10.1016/j.micpath.2022.105595, PMID 35597364, PMCID PMC9116045.

He X, He C, Hong W, Zhang K, Wei X. The challenges of COVID-19 delta variant: prevention and vaccine development. Med. 2021;2(4):846-54. doi: 10.1002/mco2.95, PMID 34909755, PMCID PMC8661803.

Tang Y, liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine storm in COVID-19: the current evidence and treatment strategies. Front Immunol. 2020;11:1708. doi: 10.3389/fimmu.2020.01708, PMID 32754163, PMCID PMC7365923.

Attiq A, Yao LJ, Afzal S, Khan MA. The triumvirate of NF-κB, inflammation and cytokine storm in COVID-19. Int Immunopharmacol. 2021;101(B):108255. doi: 10.1016/j.intimp.2021.108255, PMID 34688149, PMCID PMC8516728.

Su CM, Wang L, Yoo D. Activation of NF-κB and induction of proinflammatory cytokine expressions mediated by ORF7a protein of SARS-CoV-2. Sci Rep. 2021;11(1):13464. doi: 10.1038/s41598-021-92941-2, PMID 34188167, PMCID PMC8242070.

Zhang J, Ejikemeuwa A, Gerzanich V, Nasr M, Tang Q, Simard JM. Understanding the role of SARS-CoV-2 ORF3a in viral pathogenesis and COVID-19. Front Microbiol. 2022;13:854567. doi: 10.3389/fmicb.2022.854567, PMID 35356515, PMCID PMC8959714.

Ramasamy S, Subbian S. Critical determinants of cytokine storm and type I interferon response in COVID-19 pathogenesis. Clin Microbiol Rev. 2021;34(3). doi: 10.1128/CMR.00299-20, PMID 33980688, PMCID PMC8142516.

Kouwaki T, Nishimura T, Wang G, Oshiumi H. RIG-I-like receptor-mediated recognition of viral genomic RNA of severe acute respiratory syndrome Coronavirus-2 and viral escape from the host innate immune responses. Front Immunol. 2021;12:700926. doi: 10.3389/fimmu.2021.700926, PMID 34249006, PMCID PMC8267574.

Lanza K, Perez lG, Costa lB, Cordeiro TM, Palmeira VA, Ribeiro VT, Simoes E Silva AC. COVID-19: the renin-angiotensin system imbalance hypothesis. Clin Sci (Lond). 2020;134(11):1259-64. doi: 10.1042/CS20200492, PMCID: PMC7276636.

Silhol F, Sarlon G, Deharo JC, Vaisse B. Downregulation of ACE2 induces overstimulation of the renin-angiotensin system in COVID-19: should we block the renin-angiotensin system? Hypertens Res. 2020;43(8):854-6. doi: 10.1038/s41440-020-0476-3, PMID 32439915, PMCID PMC7242178.

Lumbers ER, Head R, Smith GR, Delforce SJ, Jarrott B, H Martin J. The interacting physiology of COVID-19 and the renin-angiotensin-aldosterone system: key agents for treatment. Pharmacol Res Perspect. 2022;10(1):e00917. doi: 10.1002/prp2.917, PMID 35106954, PMCID PMC8929333.

Elhabyan A, Elyaacoub S, Sanad E, Abukhadra A, Elhabyan A, Dinu V. The role of host genetics in susceptibility to severe viral infections in humans and insights into host genetics of severe COVID-19: a systematic review. Virus Res. 2020;289:198163. doi: 10.1016/j.virusres.2020.198163, PMID 32918943, PMCID PMC7480444.

Ovsyannikova IG, Haralambieva IH, Crooke SN, Poland GA, Kennedy RB. The role of host genetics in the immune response to SARS-CoV-2 and COVID-19 susceptibility and severity. Immunol Rev. 2020;296(1):205-19. doi: 10.1111/imr.12897, PMID 32658335, PMCID PMC7404857.

Jordan SC. Innate and adaptive immune responses to SARS-CoV-2 in humans: relevance to acquired immunity and vaccine responses. Clin Exp Immunol. 2021;204(3):310-20. doi: 10.1111/cei.13582, PMID 33534923, PMCID PMC8013613.

Varghese PM, Tsolaki AG, Yasmin H, Shastri A, Ferluga J, Vatish M. Host-pathogen interaction in COVID-19: pathogenesis, potential therapeutics and vaccination strategies. Immunobiology. 2020;225(6):152008. doi: 10.1016/j.imbio.2020.152008, PMID 33130519, PMCID PMC7434692.

Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and moderna vaccines. Eur Rev Med Pharmacol Sci. 2021;25(3):1663-9. doi: 10.26355/eurrev_202102_24877, PMID 33629336.

Livingston EH, Malani PN, Creech CB. The Johnson and Johnson vaccine for COVID-19. JAMA. 2021;325(15):1575. doi: 10.1001/jama.2021.2927, PMID 33646285.

Zatarain Barron ZL, Ramos Espinosa O, Marquina Castillo B, Barrios Payan J, Cornejo Granados F, Maya Lucas O. Evidence for the effect of vaccination on host-pathogen interactions in a murine model of pulmonary tuberculosis by mycobacterium tuberculosis. Front Immunol. 2020;11:930. doi: 10.3389/fimmu.2020.00930, PMID 32508826.

Mehta P, Swaminathan A, Yadav A, Chattopadhyay P, Shamim U, Pandey R. Integrative genomics important to understand host-pathogen interactions. Brief Funct Genomics. 2024;23(1):1-14. doi: 10.1093/bfgp/elac021, PMID 35909219.

Butler D, Mozsary C, Meydan C, Foox J, Rosiene J, Shaiber A. Shotgun transcriptome, spatial omics, and isothermal profiling of SARS-CoV-2 infection reveals unique host responses, viral diversification, and drug interactions. Nat Commun. 2021;12(1):1660. doi: 10.1038/s41467-021-21361-7, PMCID: PMC7954844.

Aggarwal S, Acharjee A, Mukherjee A, Baker MS, Srivastava S. Role of multiomics data to understand host-pathogen interactions in COVID-19 pathogenesis. J Proteome Res. 2021;20(2):1107-32. doi: 10.1021/acs.jproteome.0c00771, PMID 33426872, PMCID PMC7805606.

Zhou P, Yang XL, Wang XG, Hu B, Zhang l, Zhang W. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-3. doi: 10.1038/s41586-020-2012-7, PMCID: PMC7095418.

Meng F. SARS-CoV-2 NSP13 suppresses the hippo pathway downstream effector YAP. bioRxiv. 2023:2023-34. doi: 10.1101.2023.11.30.569413.

Soltani Zangbar MS, Parhizkar F, Ghaedi E, Tarbiat A, Motavalli R, Alizadegan A. A comprehensive evaluation of the immune system response and type-I interferon signaling pathway in hospitalized COVID-19 patients. Cell Commun Signal. 2022;20(1):106. doi: 10.1186/s12964-022-00903-6, PMID 35842705, PMCID PMC9287826.

Kircheis R, Haasbach E, Lueftenegger D, Heyken WT, Ocker M, Planz O. NF-κB pathway as a potential target for the treatment of critical stage COVID-19 patients. Front Immunol. 2020;11:598444. doi: 10.3389/fimmu.2020.598444, PMID 33362782, PMCID PMC7759159.

Butler Laporte G, Povysil G, Kosmicki JA, Cirulli ET, Drivas T, Furini S. Exome-wide association study to identify rare variants influencing COVID-19 outcomes: results from the Host Genetics Initiative. PLOS Genet. 2022;18(11):e1010367. doi: 10.1371/journal.pgen.1010367, PMID 36327219.

Mentzer AJ, O’Connor D, Bibi S, Chelysheva I, Clutterbuck EA, Demissie T. Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection. Nat Med. 2023;29(1):147-57. doi: 10.1038/s41591-022-02078-6, PMID 36228659, PMCID PMC9873562.

Quarleri J, Delpino MV. Type I and III IFN-mediated antiviral actions counteracted by SARS-CoV-2 proteins and host inherited factors. Cytokine Growth Factor Rev. 2021;58:55-65. doi: 10.1016/j.cytogfr.2021.01.003, PMID 33608189, PMCID PMC7871890.

Wang Y, Wang X, luu lDW, Chen S, Jin F, Wang S, Huang X, Wang l, Zhou X, Chen X, Cui X, li J, Tai J, Zhu X. Proteomic and metabolomic signatures associated with the immune response in healthy individuals immunized with an inactivated SARS-CoV-2 vaccine. Front Immunol. 2022;13. doi: 10.3389/fimmu.2022.848961.

Mao K, Tan Q, Ma Y, Wang S, Zhong H, liao Y. Proteomics of extracellular vesicles in plasma reveals the characteristics and residual traces of COVID-19 patients without underlying diseases after 3 mo of recovery. Cell Death Dis. 2021;12(6):541. doi: 10.1038/s41419-021-03816-3, PMID 34035220, PMCID PMC8146187.

Russell CD, Valanciute A, Gachanja NN, Stephen J, Penrice Randal R, Armstrong SD. Tissue proteomic analysis identifies mechanisms and stages of immunopathology in fatal COVID-19. Am J Respir Cell Mol Biol. 2022;66(2):196-205. doi: 10.1165/rcmb.2021-0358OC, PMID 34710339, PMCID PMC8845132.

Jose C. Metabolomics analysis reveals a modified amino acid metabolism that correlates with altered oxygen homeostasis in COVID-19 patients. Sci Rep. 2021;11.

di Flora DC, Dionizio A, Pereira HA, Garbieri TF, Grizzo lT, Dionisio TJ, Leite A de l. Analysis of plasma proteins involved in inflammation, immune response/complement system, and blood coagulation upon admission of COVID-19 patients to hospital May help to predict the prognosis of the disease. Cells. 2023;12(12):1661. doi: 10.3390/cells12121601, PMCID: PMC10297236.

Bi X, Liu W, Ding X, Liang S, Zheng Y, Zhu X. Proteomic and metabolomic profiling of urine uncovers immune responses in patients with COVID-19. Cell Rep. 2022;38(3):110271. doi: 10.1016/j.celrep.2021.110271, PMID 35026155.

Wu D, Shu T, Yang X, Song JX, Zhang M, Yao C. Plasma metabolomic and lipidomic alterations associated with COVID-19. Natl Sci Rev. 2020;7(7):1157-68. doi: 10.1093/nsr/nwaa086, PMID 34676128, PMCID PMC7197563.

Valdes A, Moreno LO, Rello SR, Orduna A, Bernardo D. Metabolomics study of COVID-19 patients in four different clinical stages. Sci Rep. 2022;12(1):1650. doi: 10.1038/s41598-022-05667-0, PMID 35102215, PMID: 35102215.

Published

07-07-2024

How to Cite

SINGH, M. S., YELLABOINA, S., & ANSARI, M. A. (2024). A COMPREHENSIVE REVIEW ON THE MULTIFACETED INTERACTIONS BETWEEN HOST IMMUNITY AND VIRAL PATHOGENESIS IN COVID-19. International Journal of Applied Pharmaceutics, 16(4), 37–45. https://doi.org/10.22159/ijap.2024v16i4.50576

Issue

Section

Review Article(s)